The Synairgen share price: here’s why I’d buy and hold this stock

The Synairgen share price has gained over 800% in the past year. With a potentially effective Covid treatment, I think this stock is a long-term opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE: SNG) share price delivered a great return on investment last year. The shares started the year at 6.34p each and ended it at 153p. The spike in price was caused by the firm’s development of a Covid-19 treatment called SNG001 and its early success. It received positive results from its phase 2 study that started in March 2020.

So far this year, Synairgen shares are up 3.7% and the 12-month return is around 838%. That said, at early Tuesday afternoon’s price of just under 157p, the stock is well below its record level of 246p from August 2020. But maybe that’s an opportunity for me. I see Synairgen as a long-term ‘buy’ as it seems Covid is here to stay, despite vaccine success.

Synairgen’s Covid-19 treatment

Synairgen was founded in 2003 by three professors who had a vision of creating a respiratory drug discovery-and-development company. But with a market capitalisation of just around £315m, it’s still a fairly small business. It has only three proprietary drug programs in its pipeline, with the most eye-catching being SNG001, its treatment for Covid-19 patients.

The company clearly differs from giant pharmaceutical companies such as Pfizer, Moderna, and AstraZeneca. They’ve focused on developing a Covid-19 vaccine, by targeting coronavirus patients instead. Synairgen has recently commenced a phase 3 trial, which is being tested in approximately 20 countries and includes 610 Covid-19 patients. 

Vaccines aren’t 100% effective and not everyone will take them. So, I firmly believe that the treatment, if approved, could potentially reduce the risk of this pandemic in the long term.

Synairgen share price outlook

That would be good news. But obviously, it’s a challenge to predict what the future holds for the company right now. The world is in wait-and-see mode, and the lasting impact of the coronavirus pandemic is not yet apparent in the global economy. But here’s why I think the business is a good buy right now — and it isn’t just because the Synairgen share price is far from its all-time high. Right now, there’s no effective treatment for Covid-19 patients. The world really needs a treatment for the disease as vaccines probably won’t eliminate it on their own.

When I look ahead, this is a key reason why I believe Synairgen is a good stock to hold for the long term. Of course, even though the price has fallen recently, the spike in the Synairgen share price over the last year makes this stock risky. And the share price is likely to drop if the company fails to achieve its targets.

But overall, I’m optimistic about the outlook. And even though Synairgen is seen as a ‘Covid-19 stock’, it’s not a one-trick pony. Its BioBank platform technology, for instance, is quite impressive. It should help Synairgen discover and develop novel therapies for respiratory diseases in general. Additionally, its pipeline portfolio includes inhaled interferon for asthma patients and a treatment for COPD.

As such, I’m going to add the stock to my portfolio today, especially following the drop in the Synairgen share price in the past week. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Chen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »